Key result
Combination therapy with capecitabine and bevacizumab resulted in a continued clinical and radiographic response after 6 months of treatment in a patient with metastatic hepatic epithelioid hemangioendothelioma.
Case Report (n=1)
No
Capecitabine and bevacizumab may represent a novel treatment option for metastatic hepatic epithelioid hemangioendothelioma.
May warrant consideration in refractory cases; leaves open efficacy pending prospective trials.
Hepatic epithelioid hemangioendothelioma (HEHE) is a rare, often misdiagnosed vascular neoplasm with clinical behaviors that range from indolent to highly aggressive. Even when the appropriate diagnosis is achieved, the best treatment for HEHE has not been defined or standardized, further complicating the care of these patients. We present a diagnostically challenging case of HEHE where we utilized capecitabine and bevacizumab as another novel treatment option.
No takes yet. Share an insight, caveat, or question.
Lau et al. (2015) conducted a case report in Metastatic hepatic epithelioid hemangioendothelioma (n=1). Capecitabine and bevacizumab was evaluated on Clinical and radiographic response. Combination therapy with capecitabine and bevacizumab resulted in a continued clinical and radiographic response after 6 months of treatment in a patient with metastatic hepatic epithelioid hemangioendothelioma.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: